International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling...
Saved in:
Published in | The American heart journal Vol. 163; no. 1; pp. 13 - 19.e1 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.01.2012
Mosby Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 0002-8703 1097-6744 1097-6744 |
DOI | 10.1016/j.ahj.2011.09.011 |
Cover
Abstract | Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.
The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient.
The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time. |
---|---|
AbstractList | Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.
The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient.
The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time. Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time. Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. Summary The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time. Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.BACKGROUNDAtrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient.DESIGNThe GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient.The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.SUMMARYThe GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time. |
Author | Mantovani, Lorenzo G. Jamal, Waheed Verheugt, Freek W.A. Turpie, Alexander G.G. Hacke, Werner Haas, Sylvia Bassand, Jean-Pierre Goto, Shinya Lip, Gregory Y.H. Fitzmaurice, David A. Mueller, Iris Kakkar, Ajay K. Rushton-Smith, Sophie Goldhaber, Samuel Z. Misselwitz, Frank |
Author_xml | – sequence: 1 givenname: Ajay K. surname: Kakkar fullname: Kakkar, Ajay K. email: akkakkar@tri-london.ac.uk organization: Thrombosis Research Institute, London, United Kingdom – sequence: 2 givenname: Iris surname: Mueller fullname: Mueller, Iris organization: Thrombosis Research Institute, London, United Kingdom – sequence: 3 givenname: Jean-Pierre surname: Bassand fullname: Bassand, Jean-Pierre organization: University Hospital Jean-Minjoz, Besançon, France – sequence: 4 givenname: David A. surname: Fitzmaurice fullname: Fitzmaurice, David A. organization: Primary Care Clinical Sciences, The University of Birmingham, Birmingham, United Kingdom – sequence: 5 givenname: Samuel Z. surname: Goldhaber fullname: Goldhaber, Samuel Z. organization: Harvard Medical School, Boston, MA – sequence: 6 givenname: Shinya surname: Goto fullname: Goto, Shinya organization: Tokai University, Kanagawa, Japan – sequence: 7 givenname: Sylvia surname: Haas fullname: Haas, Sylvia organization: Technical University of Munich, Munich, Germany – sequence: 8 givenname: Werner surname: Hacke fullname: Hacke, Werner organization: University Hospital of Heidelberg, Heidelberg, Germany – sequence: 9 givenname: Gregory Y.H. surname: Lip fullname: Lip, Gregory Y.H. organization: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom – sequence: 10 givenname: Lorenzo G. surname: Mantovani fullname: Mantovani, Lorenzo G. organization: Federico II University of Naples, Naples, Italy – sequence: 11 givenname: Freek W.A. surname: Verheugt fullname: Verheugt, Freek W.A. organization: Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands – sequence: 12 givenname: Waheed surname: Jamal fullname: Jamal, Waheed organization: Bayer Healthcare Pharmaceuticals, Berlin, Germany – sequence: 13 givenname: Frank surname: Misselwitz fullname: Misselwitz, Frank organization: Bayer Healthcare Pharmaceuticals, Berlin, Germany – sequence: 14 givenname: Sophie surname: Rushton-Smith fullname: Rushton-Smith, Sophie organization: Thrombosis Research Institute, London, United Kingdom – sequence: 15 givenname: Alexander G.G. surname: Turpie fullname: Turpie, Alexander G.G. organization: McMaster University, Hamilton, Canada |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25762111$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22172431$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkt-KEzEUxoOsuN3VB_BGAiLqRWuSyWQaBaGsu3WhIKwK3oVMJtOmTZOaZJQ-hm9spn9YKLhenST8vi-c75wLcOa80wA8x2iEEWbvliO5WI4IwniE-CiXR2CAEa-GrKL0DAwQQmQ4rlBxDi5iXOYrI2P2BJwTgitCCzwAf25d0sHJZLyTFlrv5iZ1jekvQc9NTGELfQs3mdAuRfjbpAWUKZgMtKYOxtqdOL_BYOKqh7PIr_R7OLW-ztjEJaO8nHdWugTvjq7GwbTQ8Ob2evYJvplO7nant0_B41baqJ8d6iX4fnP97erzcPZlens1mQ1Vics0pEVLKK4rRSrEFENKjgukSIPa3Frd8IaNCW0KTViFyoJTxmtSNKymmKKaS1Jcgtd7303wPzsdk1ibqHRux2nfRcEx5iViY5rJlyfk0nc5MxsFLhFlBecIZ-rFgerqtW7EJpi1DFtxzDoDrw6AjEraNkinTLznyooRjHuu2nMq-BiDboUyaZdxCtJYgZHopy-WIk9f9NMXiAu0U-IT5dH8Ic2HvUbnrH8ZHURUedJKNyZolUTjzYPqjydqZY0zub2V3up4n5OIRCDxtd_IfiExzrvI2Y9swP9t8J_P_wL6--1I |
CODEN | AHJOA2 |
CitedBy_id | crossref_primary_10_1016_j_ijcard_2016_01_196 crossref_primary_10_1007_s40256_019_00371_3 crossref_primary_10_1136_openhrt_2023_002506 crossref_primary_10_3399_BJGP_2021_0548 crossref_primary_10_1093_europace_euz292 crossref_primary_10_1016_j_jjcc_2022_03_006 crossref_primary_10_1161_CIRCULATIONAHA_118_035012 crossref_primary_10_1186_s12872_016_0308_1 crossref_primary_10_1007_s12325_024_02895_w crossref_primary_10_1016_j_ijcha_2019_100461 crossref_primary_10_26442_00403660_2022_12_201994 crossref_primary_10_1016_j_amjmed_2016_06_004 crossref_primary_10_1136_bmj_2021_066450 crossref_primary_10_1371_journal_pone_0177519 crossref_primary_10_1002_clc_23279 crossref_primary_10_1016_j_jelectrocard_2019_02_011 crossref_primary_10_1161_CIRCULATIONAHA_123_068239 crossref_primary_10_1186_s12959_020_00218_x crossref_primary_10_1002_clc_23558 crossref_primary_10_3390_healthcare11050638 crossref_primary_10_1001_jamanetworkopen_2020_0107 crossref_primary_10_1182_bloodadvances_2020003560 crossref_primary_10_1161_CIRCULATIONAHA_123_064556 crossref_primary_10_1160_TH12_06_0438 crossref_primary_10_1080_00015385_2018_1494089 crossref_primary_10_2459_JCM_0000000000001007 crossref_primary_10_3390_diagnostics13040613 crossref_primary_10_17816_cardar321821 crossref_primary_10_1016_j_ahj_2013_12_006 crossref_primary_10_1016_j_acmx_2016_11_003 crossref_primary_10_1111_jce_14176 crossref_primary_10_1136_bmjopen_2016_014579 crossref_primary_10_2174_1381612826666201210113328 crossref_primary_10_1016_j_ahj_2014_04_007 crossref_primary_10_1016_j_acmx_2016_11_006 crossref_primary_10_1517_14740338_2015_1049995 crossref_primary_10_1016_j_jsha_2012_08_001 crossref_primary_10_1016_j_acvd_2018_03_012 crossref_primary_10_1093_eurheartj_suv037 crossref_primary_10_1093_eurheartj_suv038 crossref_primary_10_1186_s12877_024_05186_9 crossref_primary_10_1016_j_ahj_2017_08_011 crossref_primary_10_1136_bmjopen_2018_025901 crossref_primary_10_1517_14740338_2015_973847 crossref_primary_10_1002_agm2_12214 crossref_primary_10_1093_eurheartj_suv035 crossref_primary_10_1161_CIRCULATIONAHA_113_003825 crossref_primary_10_1517_14656566_2014_938638 crossref_primary_10_1016_j_jacc_2020_07_045 crossref_primary_10_1160_TH13_09_0741 crossref_primary_10_1016_j_ahj_2023_06_007 crossref_primary_10_4081_btvb_2023_97 crossref_primary_10_1016_j_rccl_2020_10_015 crossref_primary_10_1136_openhrt_2024_002966 crossref_primary_10_1016_j_amjmed_2023_10_027 crossref_primary_10_1161_JAHA_118_010510 crossref_primary_10_1002_clc_23176 crossref_primary_10_1093_ehjqcco_qcaa050 crossref_primary_10_1007_s12471_016_0874_y crossref_primary_10_1111_jth_15415 crossref_primary_10_1093_ehjqcco_qcab028 crossref_primary_10_17116_kardio202417061670 crossref_primary_10_20996_1819_6446_2023_03_07 crossref_primary_10_1186_s12959_019_0195_7 crossref_primary_10_1016_j_ijcard_2016_08_236 crossref_primary_10_1093_ehjqcco_qcx003 crossref_primary_10_1080_20009666_2019_1593781 crossref_primary_10_15690_vramn1116 crossref_primary_10_2217_fnl_15_43 crossref_primary_10_1016_j_amjmed_2023_08_019 crossref_primary_10_1093_ehjdh_ztac011 crossref_primary_10_1007_s11739_021_02672_5 crossref_primary_10_1007_s00059_020_04930_2 crossref_primary_10_1177_0003319714536980 crossref_primary_10_1002_pst_2211 crossref_primary_10_1016_j_amjmed_2019_06_008 crossref_primary_10_1371_journal_pone_0063479 crossref_primary_10_2217_fca_15_31 crossref_primary_10_1161_JAHA_124_036417 crossref_primary_10_1093_ehjqcco_qcac068 crossref_primary_10_3390_jcm10040573 crossref_primary_10_1161_JAHA_116_004037 crossref_primary_10_23736_S2724_5683_22_05891_4 crossref_primary_10_1016_j_ahj_2021_09_003 crossref_primary_10_1080_07853890_2021_1893897 crossref_primary_10_1097_MD_0000000000025725 crossref_primary_10_1161_CIRCOUTCOMES_114_001556 crossref_primary_10_1111_jth_15081 crossref_primary_10_1136_openhrt_2024_002708 crossref_primary_10_1161_JAHA_114_001179 crossref_primary_10_1136_bmjopen_2017_018905 crossref_primary_10_1093_ehjqcco_qcx030 crossref_primary_10_15829_1728_8800_2013_1_4_9 crossref_primary_10_3399_BJGP_2023_0082 crossref_primary_10_1016_j_amjmed_2016_09_012 crossref_primary_10_18087_cardio_2023_10_n2284 crossref_primary_10_1093_europace_eux193 crossref_primary_10_1160_TH16_06_0485 crossref_primary_10_1136_heartjnl_2020_318420 crossref_primary_10_1161_JAHA_118_011427 crossref_primary_10_1111_dom_15202 crossref_primary_10_2196_resprot_8523 crossref_primary_10_38109_2225_1685_2017_4_40_51 crossref_primary_10_1016_j_trsl_2017_03_004 crossref_primary_10_1186_1471_2261_13_31 crossref_primary_10_1161_CIRCOUTCOMES_114_001263 crossref_primary_10_26442_00403660_2020_09_000655 crossref_primary_10_1080_14740338_2024_2409698 crossref_primary_10_1001_jamacardio_2018_4729 crossref_primary_10_1016_j_acmx_2015_04_001 crossref_primary_10_1136_openhrt_2023_002275 crossref_primary_10_1007_s00392_022_02079_y crossref_primary_10_1016_j_ahj_2016_03_001 crossref_primary_10_1155_2014_567026 crossref_primary_10_1177_1753944716643645 crossref_primary_10_1093_ehjqcco_qcz047 crossref_primary_10_1016_j_ijcard_2015_06_088 crossref_primary_10_3238_PersKardio_2016_03_25_06 crossref_primary_10_1093_ehjqcco_qcw058 crossref_primary_10_1093_ehjcvp_pvz076 crossref_primary_10_1136_bmjopen_2021_049933 crossref_primary_10_1136_openhrt_2022_002038 crossref_primary_10_1016_j_ccep_2013_10_006 crossref_primary_10_1111_bjh_14084 crossref_primary_10_1371_journal_pone_0191592 crossref_primary_10_1378_chest_12_1091 crossref_primary_10_1111_ijcp_14313 crossref_primary_10_1159_000352062 crossref_primary_10_1016_j_hlc_2017_05_131 crossref_primary_10_1160_TH13_12_1007 crossref_primary_10_1371_journal_pone_0259199 crossref_primary_10_1111_iju_13725 crossref_primary_10_1136_bmjopen_2017_017157 crossref_primary_10_4081_btvb_2023_84 crossref_primary_10_1002_clc_22811 crossref_primary_10_1161_CIRCOUTCOMES_115_002369 crossref_primary_10_1016_j_hrthm_2018_09_021 crossref_primary_10_1136_heartjnl_2016_309832 crossref_primary_10_1159_000478895 crossref_primary_10_1016_j_amjmed_2021_01_017 crossref_primary_10_1016_j_ijcard_2018_03_060 crossref_primary_10_2310_JIM_0b013e31828df1bf crossref_primary_10_1093_eurheartj_ehw233 crossref_primary_10_1016_j_ijcha_2023_101302 crossref_primary_10_1016_j_ctim_2016_02_014 crossref_primary_10_1111_jcpt_12634 crossref_primary_10_1161_JAHA_117_007537 crossref_primary_10_1016_j_ajem_2016_09_047 crossref_primary_10_1136_openhrt_2015_000335 crossref_primary_10_1080_17843286_2022_2123483 crossref_primary_10_1002_clc_24109 crossref_primary_10_1016_j_jacc_2014_10_052 crossref_primary_10_1093_ehjopen_oead051 crossref_primary_10_1371_journal_pone_0164076 crossref_primary_10_1111_jep_13316 crossref_primary_10_2146_ajhp150959 crossref_primary_10_1002_joa3_12034 crossref_primary_10_1016_j_ijcard_2024_132866 crossref_primary_10_1007_s11739_020_02442_9 crossref_primary_10_1093_eurheartj_ehx730 crossref_primary_10_15829_1560_4071_2021_4635 crossref_primary_10_1016_j_jacc_2015_02_010 crossref_primary_10_1136_openhrt_2024_003109 crossref_primary_10_1093_europace_euaa172 crossref_primary_10_2217_fca_2020_0014 crossref_primary_10_38109_2225_1685_2019_4_4_85 crossref_primary_10_1007_s40265_017_0699_z crossref_primary_10_1016_j_acvd_2014_01_001 crossref_primary_10_1055_a_1333_4448 crossref_primary_10_36740_WLek202103115 crossref_primary_10_1007_s12325_021_01670_5 crossref_primary_10_1371_journal_pone_0196666 crossref_primary_10_1007_s40256_016_0161_8 crossref_primary_10_1136_openhrt_2018_000788 crossref_primary_10_15829_1728_8800_2014_6_3_8 crossref_primary_10_1016_j_jjcc_2018_09_003 crossref_primary_10_5853_jos_2016_00157 crossref_primary_10_1253_circj_CJ_18_0655 crossref_primary_10_1002_ehf2_13156 crossref_primary_10_1016_j_ahj_2019_03_013 crossref_primary_10_1177_1747493019891516 |
Cites_doi | 10.1378/chest.10-0134 10.1001/jama.285.18.2370 10.1093/eurheartj/ehl015 10.1016/j.ahj.2008.06.029 10.1056/NEJMoa1009638 10.1056/NEJMoa0905561 10.1093/europace/euq350 10.1016/j.jacc.2005.06.077 10.1136/bmj.39280.660567.55 10.1016/j.ahj.2009.07.035 10.1016/j.ahj.2009.08.026 10.1016/j.amjmed.2009.12.013 10.1093/eurheartj/ehm358 10.1016/j.amjcard.2008.10.017 10.1016/j.amjmed.2005.10.057 10.1016/j.jacc.2010.05.025 10.1093/europace/eun369 10.1136/bmj.d124 10.1093/eurheartj/ehq278 10.1001/jama.297.11.1197 10.1136/heart.86.5.516 10.1136/hrt.2009.190827 |
ContentType | Journal Article |
Copyright | 2012 Mosby, Inc. Mosby, Inc. 2015 INIST-CNRS Copyright © 2012 Mosby, Inc. All rights reserved. Copyright Elsevier Limited Jan 2012 |
Copyright_xml | – notice: 2012 Mosby, Inc. – notice: Mosby, Inc. – notice: 2015 INIST-CNRS – notice: Copyright © 2012 Mosby, Inc. All rights reserved. – notice: Copyright Elsevier Limited Jan 2012 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QO 7RV 7TS 7X7 7XB 88C 88E 8AO 8C1 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O MBDVC NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7X8 |
DOI | 10.1016/j.ahj.2011.09.011 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Nursing & Allied Health Database Physical Education Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database - QC Medical Database Research Library Research Library (Corporate) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection Physical Education Index ProQuest Central Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Research Library Prep MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6744 |
EndPage | 19.e1 |
ExternalDocumentID | 3238418451 22172431 25762111 10_1016_j_ahj_2011_09_011 S000287031100696X 1_s2_0_S000287031100696X |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 23M 354 3O- 4.4 41~ 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 7RV 7X7 88E 8AO 8C1 8F7 8FI 8FJ 8G5 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABPPZ ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIWK ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI C45 CAG CCPQU COF CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HEB HMCUK HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M0T M1P M29 M2O M41 MO0 N4W N9A NAPCQ O-L O9- OA. OAUVE OBH OHH OHT OL~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UGJ UHS UKHRP UKR UV1 WH7 WOW WUQ X7M XCE YOC YYM YYP Z5R ZGI ZXP ZY1 ~G- 3V. AACTN AAYOK AFCTW AFKWA AJOXV AMFUW PKN RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX CITATION ~HD AGRNS IQODW CGR CUY CVF ECM EIF NPM 7QO 7TS 7XB 8FD 8FK FR3 K9. MBDVC P64 PKEHL PQEST PQUKI Q9U 7X8 |
ID | FETCH-LOGICAL-c515t-43f241b7c2706c60ca830c2d0f172bd9d6824d3e2670539469b23d6b4140b9a23 |
IEDL.DBID | .~1 |
ISSN | 0002-8703 1097-6744 |
IngestDate | Fri Sep 05 09:34:37 EDT 2025 Sun Sep 07 03:33:51 EDT 2025 Mon Jul 21 06:02:07 EDT 2025 Mon Jul 21 09:15:05 EDT 2025 Thu Apr 24 22:58:40 EDT 2025 Thu Sep 18 00:27:26 EDT 2025 Fri Feb 23 02:34:20 EST 2024 Sun Feb 23 10:19:24 EST 2025 Tue Aug 26 17:16:42 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Human Nervous system diseases Stroke Arrhythmia Atrial fibrillation Patient Cardiovascular disease Risk Anticoagulant Excitability disorder Cerebral disorder Vascular disease Heart disease Central nervous system disease Risk factor Circulatory system Cardiology Cerebrovascular disease International |
Language | English |
License | CC BY 4.0 Copyright © 2012 Mosby, Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c515t-43f241b7c2706c60ca830c2d0f172bd9d6824d3e2670539469b23d6b4140b9a23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 22172431 |
PQID | 1504639901 |
PQPubID | 2031075 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_911950684 proquest_journals_1504639901 pubmed_primary_22172431 pascalfrancis_primary_25762111 crossref_citationtrail_10_1016_j_ahj_2011_09_011 crossref_primary_10_1016_j_ahj_2011_09_011 elsevier_sciencedirect_doi_10_1016_j_ahj_2011_09_011 elsevier_clinicalkeyesjournals_1_s2_0_S000287031100696X elsevier_clinicalkey_doi_10_1016_j_ahj_2011_09_011 |
PublicationCentury | 2000 |
PublicationDate | January 2012 2012 2012-01-00 2012-Jan 20120101 |
PublicationDateYYYYMMDD | 2012-01-01 |
PublicationDate_xml | – month: 01 year: 2012 text: January 2012 |
PublicationDecade | 2010 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States – name: Philadelphia |
PublicationTitle | The American heart journal |
PublicationTitleAlternate | Am Heart J |
PublicationYear | 2012 |
Publisher | Elsevier Inc Mosby Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Mosby – name: Elsevier Limited |
References | Lip, Halperin (bb0095) 2010; 123 Fitzmaurice, Hobbs, Jowett (bb0015) 2007; 335 Steg, Bhatt, Wilson (bb0075) 2007; 297 Kirchhof, Auricchio, Bax (bb0025) 2007; 28 Connolly, Ezekowitz, Yusuf (bb0060) 2009; 361 Fein, Wang, Curtis (bb0030) 2010; 56 McCabe, Johnson, Marcus (bb0040) 2009; 103 Camm, Kirchhof, Lip (bb0115) 2010; 12 Waldo, Becker, Tapson (bb0105) 2005; 46 Nabauer, Gerth, Limbourg (bb0035) 2009; 11 Nieuwlaat, Capucci, Lip (bb0045) 2006; 27 European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm (bb0065) 2010; 31 Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. American Journal of Medicine 2006;119:448 e1-19. Fox, Eagle, Gore (bb0070) 2010; 96 Go, Hylek, Phillips (bb0010) 2001; 285 Lopes, Alexander, Al-Khatib (bb0055) 2010; 159 Patel, Mahaffey, Garg (bb0110) 2011; 365 Stewart, Hart, Hole (bb0005) 2001; 86 Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal 2010;159:348-53 e1. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-63, 63 e2. Aguilar, Hart, Pearce (bb0085) 2007 Olesen, Lip, Hansen (bb0090) 2011; 342 Pisters, Lane, Nieuwlaat (bb0100) 2010; 138 Steg (10.1016/j.ahj.2011.09.011_bb0075) 2007; 297 Olesen (10.1016/j.ahj.2011.09.011_bb0090) 2011; 342 10.1016/j.ahj.2011.09.011_bb0020 Patel (10.1016/j.ahj.2011.09.011_bb0110) 2011; 365 10.1016/j.ahj.2011.09.011_bb0050 Pisters (10.1016/j.ahj.2011.09.011_bb0100) 2010; 138 Fitzmaurice (10.1016/j.ahj.2011.09.011_bb0015) 2007; 335 Kirchhof (10.1016/j.ahj.2011.09.011_bb0025) 2007; 28 Camm (10.1016/j.ahj.2011.09.011_bb0115) 2010; 12 10.1016/j.ahj.2011.09.011_bb0080 Waldo (10.1016/j.ahj.2011.09.011_bb0105) 2005; 46 Nabauer (10.1016/j.ahj.2011.09.011_bb0035) 2009; 11 Connolly (10.1016/j.ahj.2011.09.011_bb0060) 2009; 361 Aguilar (10.1016/j.ahj.2011.09.011_bb0085) 2007 Nieuwlaat (10.1016/j.ahj.2011.09.011_bb0045) 2006; 27 Fein (10.1016/j.ahj.2011.09.011_bb0030) 2010; 56 Lip (10.1016/j.ahj.2011.09.011_bb0095) 2010; 123 Lopes (10.1016/j.ahj.2011.09.011_bb0055) 2010; 159 McCabe (10.1016/j.ahj.2011.09.011_bb0040) 2009; 103 Stewart (10.1016/j.ahj.2011.09.011_bb0005) 2001; 86 Go (10.1016/j.ahj.2011.09.011_bb0010) 2001; 285 Fox (10.1016/j.ahj.2011.09.011_bb0070) 2010; 96 European Heart Rhythm Association (10.1016/j.ahj.2011.09.011_bb0065) 2010; 31 |
References_xml | – volume: 86 start-page: 516 year: 2001 end-page: 521 ident: bb0005 article-title: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study publication-title: Heart – volume: 31 start-page: 2369 year: 2010 end-page: 2429 ident: bb0065 article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) publication-title: Eur Heart J – volume: 297 start-page: 1197 year: 2007 end-page: 1206 ident: bb0075 article-title: One-year cardiovascular event rates in outpatients with atherothrombosis publication-title: JAMA – reference: Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal 2010;159:348-53 e1. – volume: 335 start-page: 383 year: 2007 ident: bb0015 article-title: Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial publication-title: BMJ – volume: 159 start-page: 331 year: 2010 end-page: 339 ident: bb0055 article-title: Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale publication-title: Am Heart J – volume: 96 start-page: 1095 year: 2010 end-page: 1101 ident: bb0070 article-title: The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE publication-title: Heart – reference: Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. American Journal of Medicine 2006;119:448 e1-19. – volume: 361 start-page: 1139 year: 2009 end-page: 1151 ident: bb0060 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med – volume: 138 start-page: 1093 year: 2010 end-page: 1100 ident: bb0100 article-title: A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey publication-title: Chest – volume: 28 start-page: 2803 year: 2007 end-page: 2817 ident: bb0025 article-title: Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) publication-title: Eur Heart J – volume: 11 start-page: 423 year: 2009 end-page: 434 ident: bb0035 article-title: The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management publication-title: Europace – volume: 27 start-page: 3018 year: 2006 end-page: 3026 ident: bb0045 article-title: Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation publication-title: Eur Heart J – reference: Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-63, 63 e2. – volume: 56 start-page: 766 year: 2010 end-page: 773 ident: bb0030 article-title: Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry publication-title: J Am Coll Cardiol – volume: 46 start-page: 1729 year: 2005 end-page: 1736 ident: bb0105 article-title: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation publication-title: J Am Coll Cardiol – start-page: CD006186 year: 2007 ident: bb0085 article-title: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks publication-title: Cochrane Database Syst Rev – volume: 365 start-page: 883 year: 2011 end-page: 891 ident: bb0110 article-title: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation publication-title: N Engl J Med – volume: 12 start-page: 1360 year: 2010 end-page: 1420 ident: bb0115 article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) publication-title: Europace – volume: 103 start-page: 535 year: 2009 end-page: 539 ident: bb0040 article-title: Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation publication-title: Am J Cardiol – volume: 285 start-page: 2370 year: 2001 end-page: 2375 ident: bb0010 article-title: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study publication-title: JAMA – volume: 342 start-page: d124 year: 2011 ident: bb0090 article-title: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study publication-title: BMJ – volume: 123 start-page: 484 year: 2010 end-page: 488 ident: bb0095 article-title: Improving stroke risk stratification in atrial fibrillation publication-title: Am J Med – volume: 138 start-page: 1093 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0100 article-title: A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey publication-title: Chest doi: 10.1378/chest.10-0134 – volume: 285 start-page: 2370 year: 2001 ident: 10.1016/j.ahj.2011.09.011_bb0010 article-title: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study publication-title: JAMA doi: 10.1001/jama.285.18.2370 – volume: 27 start-page: 3018 year: 2006 ident: 10.1016/j.ahj.2011.09.011_bb0045 article-title: Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation publication-title: Eur Heart J doi: 10.1093/eurheartj/ehl015 – start-page: CD006186 year: 2007 ident: 10.1016/j.ahj.2011.09.011_bb0085 article-title: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks publication-title: Cochrane Database Syst Rev – ident: 10.1016/j.ahj.2011.09.011_bb0080 doi: 10.1016/j.ahj.2008.06.029 – volume: 365 start-page: 883 year: 2011 ident: 10.1016/j.ahj.2011.09.011_bb0110 article-title: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 – volume: 361 start-page: 1139 year: 2009 ident: 10.1016/j.ahj.2011.09.011_bb0060 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 – volume: 12 start-page: 1360 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0115 article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) publication-title: Europace doi: 10.1093/europace/euq350 – volume: 46 start-page: 1729 year: 2005 ident: 10.1016/j.ahj.2011.09.011_bb0105 article-title: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.06.077 – volume: 335 start-page: 383 year: 2007 ident: 10.1016/j.ahj.2011.09.011_bb0015 article-title: Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial publication-title: BMJ doi: 10.1136/bmj.39280.660567.55 – volume: 159 start-page: 331 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0055 article-title: Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale publication-title: Am Heart J doi: 10.1016/j.ahj.2009.07.035 – ident: 10.1016/j.ahj.2011.09.011_bb0050 doi: 10.1016/j.ahj.2009.08.026 – volume: 123 start-page: 484 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0095 article-title: Improving stroke risk stratification in atrial fibrillation publication-title: Am J Med doi: 10.1016/j.amjmed.2009.12.013 – volume: 28 start-page: 2803 year: 2007 ident: 10.1016/j.ahj.2011.09.011_bb0025 article-title: Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehm358 – volume: 103 start-page: 535 year: 2009 ident: 10.1016/j.ahj.2011.09.011_bb0040 article-title: Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2008.10.017 – ident: 10.1016/j.ahj.2011.09.011_bb0020 doi: 10.1016/j.amjmed.2005.10.057 – volume: 56 start-page: 766 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0030 article-title: Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2010.05.025 – volume: 11 start-page: 423 year: 2009 ident: 10.1016/j.ahj.2011.09.011_bb0035 article-title: The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management publication-title: Europace doi: 10.1093/europace/eun369 – volume: 342 start-page: d124 year: 2011 ident: 10.1016/j.ahj.2011.09.011_bb0090 article-title: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study publication-title: BMJ doi: 10.1136/bmj.d124 – volume: 31 start-page: 2369 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0065 article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehq278 – volume: 297 start-page: 1197 year: 2007 ident: 10.1016/j.ahj.2011.09.011_bb0075 article-title: One-year cardiovascular event rates in outpatients with atherothrombosis publication-title: JAMA doi: 10.1001/jama.297.11.1197 – volume: 86 start-page: 516 year: 2001 ident: 10.1016/j.ahj.2011.09.011_bb0005 article-title: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study publication-title: Heart doi: 10.1136/heart.86.5.516 – volume: 96 start-page: 1095 year: 2010 ident: 10.1016/j.ahj.2011.09.011_bb0070 article-title: The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE publication-title: Heart doi: 10.1136/hrt.2009.190827 |
SSID | ssj0006286 |
Score | 2.4793026 |
Snippet | Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of... Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 13 |
SubjectTerms | Anticoagulants Anticoagulants - administration & dosage Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality Biological and medical sciences Blood clots Blood. Blood coagulation. Reticuloendothelial system Cardiac dysrhythmias Cardiology. Vascular system Cardiovascular Clinical medicine Cohort Studies Global Health Heart Humans Longitudinal Studies Medical sciences Multicenter Studies as Topic Neurology Patient Selection Pharmacology. Drug treatments Prospective Studies Recruitment Registries Research Design Risk Factors Stroke Stroke - complications Stroke - drug therapy Stroke - mortality Vascular diseases and vascular malformations of the nervous system Veins & arteries |
SummonAdditionalLinks | – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLZgSAgJTeM2AtvkBx4AKeA4rhPzgqqxMhDjYTCpb5YviWBUSSHtD9k_5hzHSTWJFfWhVWs7aXwun4-Pz0fIC1EacDNCpbKWk1Q46VNVFz4tvVF1Zr23gWzi7Ks8vRCf55N5DLh1Ma1ysInBUPvWYYz8LQAXgd6UZe-Xv1NkjcLd1UihcZvcycAGo2KWx5sUDzx2OcJfEO1hVzPkd5kfl7GCp3rDsuwmv3R_aTp4WnVPc3EzDg3-aLZHdiOQpNN-5h-QW1XzkNw9i1vlj8jVtVgfXbRITLT2SIJFkY0BSd5oW9NYWLWjGJGlJrB40BoPAiz6NDn4jmICOjaGTu2v6h3tmQLotIGLtwbZ7JsVPR9G_dlQgJV09unkywf68uP0PHx69ZhczE6-H5-mkX8hdYByVqnIa_DvtnC8YNJJ5kyZM8c9qwH1WK-8LLnwecVlAaqsYKFtee6lFbBos8rw_AnZadqmekoonzh4SV8prDDonRU5DFjakpusBFFJCBuevnaxODlyZCz0kIV2qWHCNE6YZkrDW0Jej12WfWWObY35MKV6OHIKRlKD39jWqfhXp6qLat7pTHdcM_0tBCmRCSDDys9ynhAx9oxIpkco_7vg0TVpG_8XrgphpQ4NDgbx05ubGDUjIXT8GawEbv2YpmrXnVaB7leWIiH7vdRuxkaKMoCRz7aP_ZzcgzvlffTpgOys_qyrQ8BjK3sUlO4vf40wuw priority: 102 providerName: ProQuest |
Title | International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S000287031100696X https://www.clinicalkey.es/playcontent/1-s2.0-S000287031100696X https://dx.doi.org/10.1016/j.ahj.2011.09.011 https://www.ncbi.nlm.nih.gov/pubmed/22172431 https://www.proquest.com/docview/1504639901 https://www.proquest.com/docview/911950684 |
Volume | 163 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemISEkhPheYEx-4AGQsiWO68S8ldLSAatQxaS-Wf5IREeVVKR95X_gP-YucVJVsCGhSkma-hzXPvvOuY8fIS95pkHMcBmKQgxCboULZZG6MHNaFrFxzjRgExczMb3kHxeDxQEZdbEw6Fbp1_52TW9Wa3_nzPfm2Xq5xBjfCK10CSY9E1IsMIKdp8jrpz93bh4YetmrwFC6s2w2Pl7625XP4ilPozi-TjbdXesaeqxooS6u10UbmTS5T-55ZZIO2_Y-IAd5-ZDcvvDm8kfk1977PrqqEJxo6xAIiyIiAwK90aqgPrlqTfGtLNUNkgctMBhg1brKwT2KTuhYGIiq7_lb2qIF0GEJD680ItqXGzrval2WFFRLOjkff35PX30Yzpur14_J5WT8dTQNPQZDaEHT2YQ8KUDGm9SyNBJWRFZnSWSZiwrQfIyTTmSMuyRnIoXpLGGzbVjihOGwcTNSs-QJOSyrMj8ilA0sfITLJWYZdNbwBCrMTMZ0nAG7BCTqel9Zn6AccTJWqvNEu1IwYAoHTEVSwSkgb3qSdZud46bCrBtS1YWdwkKpQHbcRJT-jSiv_VSvVaxqpiL1BzsGhPeUexz9rwee7HFb_79wZwi7dShw3LGf2jVigJnf0MYZENr_DCsFmn90mVfbWskG8ldkPCBPW67d1Y0wZaBKPvu_Nj8nd-AbuviAVD8mh5sf2_wF6Gobc9JMRjimixSO2Qiubw3PP01ncH43nn2Z_waL_D5X |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIQHShPhPYAw_gARIGYnjOjESQtW20rJ2D2OT-mZiOxmMKimkFeJj8EX4jNwlcapJrDxNeWiU-uy0d747n8_3I-Q5T1IwM1z6Ihc9nxthfZnH1k9sKvNQW6trsInJkRie8o_T3nSD_HFnYTCt0unEWlHb0mCM_A04LhytaRC-n3_3ETUKd1cdhEYjFofZr5-wZKvejfaBvy8YGxyc7A39FlXAN2C7Fz6PcrBaOjYsDoQRgUmTKDDMBjnYcm2lFQnjNsqYiEFAJSwfNYus0ByWIlqmWOgAVP41HkUCU8iSvVVKCR7z7NxtmEpuF7XOJ0u_nLcVQ-VuEIaX2cGteVoBd_IGVuNyv7e2f4Pb5FbruNJ-I2l3yEZW3CXXJ-3W_D3y-0Jskc5KBEJaWgTdooj-gKBytMxpW8i1ohgBpmmNGkJzPHgwa9Ly4BnFhHdsDETlt-wtbZAJaL-Awcv0bDkDeaDHrtevBQU3lg5GB-N9-vJD_7i-e3WfnF4JZx6QzaIsskeEsp6BS9hMYkVDazSPoMNEJywNExBNjwTu31emLYaOmBwz5bLezhUwTCHDVCAVfHjkdUcybyqBrGvMHEuVO-IKSlmBnVpHFP-LKKtatVKpUFVMBepTHRRF5IEQK02LqUd4R9l6To1H9L8Bdy5IW_e7cBXKQmyw7cRPrV6im4keod3XoJVwqyktsnJZKVnDC4uEe-RhI7WrvhESDdzWx-v7fkZuDE8mYzUeHR0-ITfhrVkT-domm4sfy-wp-IILvVNPQEo-X_WM_wvQSWtp |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELamTpqQEOKdwBj-ABIghSWO6yRIEyq0ZWVbNRUm9ZvnlwQYVVNIK8TP4G_xq7hLnEyTWPk09UOrxnaT3p2fs313DyFPeaIAZnjqi1x0fW6E9dM8tn5iVZqH2lpdkU0cjcX-Cf8w7U43yJ8mFwbDKps5sZqobWFwj3wXHBeOaBqEu7kLizjuD98svvvIIIUnrQ2dhnI0C3avKjfmkjwOsl8_YTlX7o36IPtnjA0Hn97t-45xwDeA60ufRzkgmo4NiwNhRGBUEgWG2SAHnNc2tSJh3EYZEzEobwpLS80iKzSHZYpOFRZBADjYjAElWYdsvh2MjyctLmASaOuMg6E1Z6xVtJn6cubqiaavgjC8DCWvL1QJsstr0o3LveIKHYc3yQ3n1tJerYe3yEY2v022jtzB_R3y-8LOI50VSJO0skjJRZEbAinnaJFTV-a1pLg_TFXFKUJzTEuY1UF78B3FcHhsDJ2Kb9lrWvMW0B5IwxTq82oG2kInzahf5xScXDocDQ779Pn73qT69OIuObkS2dwjnXkxzx4QyroGXsJmKdY7tEbzCAZMdMJUmIDieiRo_n1pXKl0ZOyYySYm7kyCwCQKTAaphDePvGy7LOo6Iesas0akskmAhSlbAoqt6xT_q1NWukmnlKEsmQzkx2rLFHkJQqxDLaYe4W1P51fV_tL_fnDngra1z4VrVBZig-1G_eT5TbR26hHaXoY5Cw-i1DwrVqVMK_JhkXCP3K-19nxsJEwDp_bh-rGfkC2wfnk4Gh88Itfgplm9LbZNOssfq-wxOIpLveMskJLTqzb6vy-UdmA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+longitudinal+registry+of+patients+with+atrial+fibrillation+at+risk+of+stroke%3A+Global+Anticoagulant+Registry+in+the+FIELD+%28GARFIELD%29&rft.jtitle=The+American+heart+journal&rft.au=Kakkar%2C+Ajay+K.%2C+MBBS%2C+PhD&rft.au=Mueller%2C+Iris%2C+MD&rft.au=Bassand%2C+Jean-Pierre%2C+MD&rft.au=Fitzmaurice%2C+David+A.%2C+MD&rft.date=2012&rft.issn=0002-8703&rft.volume=163&rft.issue=1&rft.spage=13&rft.epage=19.e1&rft_id=info:doi/10.1016%2Fj.ahj.2011.09.011&rft.externalDBID=ECK1-s2.0-S000287031100696X&rft.externalDocID=1_s2_0_S000287031100696X |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00028703%2FS0002870311X00133%2Fcov150h.gif |